Atricure announces 510(k) clearance for the cryoform™
cryoablation probe
Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in treatments for atrial fibrillation (afib) and left atrial appendage management, today announced that it has received 510(k) clearance for the cryoform cryoablation probe, which offers increased probe flexibility to adapt to a variety of surgical ablation procedures. the probe was previously launched in october 2015 in the european market under a ce mark. “we are excited to bring this new technology to the u.s. market,” said mike carrel, president and ceo of atricure. “since the launch in europe, we have received very positive feedback from our customers, and are looking forward to continued growth in our cryoablation platform.” the cryoform probe builds off of the company’s core strengths in cryoablation technology, leveraging such important features as thermal capacity to remove heat and active defrost, which offers the increased probe flexibility necessary for minimally invasive cardiac surgeries. building upon those strengths, the new probe offers increased flexibility, allowing the surgeon to more easily manipulate and apply the device and conform to challenging anatomies. “the flexibility of cryoform, together with the automatic defrost function of the cryoice system, made us decide at the heart center leipzig to start using this product for our cryoablation procedures,” said dr. martin misfield, md, phd, professor and co-director, department of cardiac surgery, heart center, university of leipzig. about atricure atricure, inc. is a medical device company providing innovative atrial fibrillation (afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. atricure’s synergy™ ablation system is the first and only surgical device approved for the treatment of persistent and longstanding persistent forms of afib in patients undergoing certain open concomitant procedures. atricure’s atriclip® left atrial appendage management (laam) exclusion device is the most widely sold device worldwide that’s indicated for the occlusion of the left atrial appendage. the company believes cardiothoracic surgeons are adopting its ablation and laam devices for the treatment of afib and reduction of afib related complications such as stroke. atricure recently acquired ncontact, a leader in minimally invasive technology for epicardial ablation. ncontact’s mission is to transform the underserved arrhythmia population through a multidisciplinary epicardial-endocardial ablation approach. afib affects more than 33 million people worldwide. for more information visit atricure.com or follow us on twitter @atricure.
ATRC Ratings Summary
ATRC Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission